Mazdutide

PeptideXpo primary owner

Overview

Mazdutide (development codes IBI362 / LY3305677) is an investigational dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics in partnership with Eli Lilly. Unlike the GIP/GLP-1 dual agonist class (Tirzepatide) or the GIP/GLP-1/glucagon tri-agonist class (Retatrutide), Mazdutide engages only the GLP-1 and glucagon arms, without GIP, which positions it as a mechanistically distinct alternative for buyers studying glucagon-pathway pharmacology in isolation from GIP signaling. The molecule is in Phase 3 development in China for chronic weight management and type 2 diabetes, with regulatory approval signals expected on a faster timeline in the Chinese market than Western markets. PeptideXpo supplies Mazdutide acetate as a lyophilized powder at ≥99.0% HPLC purity with batch-specific COA. The analytical packet covers peak-integration HPLC, ESI mass spec, water content, and counter-ion; sequence verification by LC-MS/MS is available when required by a written analytical scope. The 10 mg standard fill size covers typical research aliquot work; larger fills for sustained-research programs are available through the OEM service.

Who buys this, and why

Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

2259884-03-0

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

5 mg – 10 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 1075.7 hours

MOQ

On request

Lead time

14–21 days

Storage

2–8°C, protect from light

Documentation available on request

• Certificate of Analysis (COA)
• HPLC Chromatogram
• Mass-spec identity (ESI-MS)
• Counter-ion / residual solvent
• Bacterial endotoxin (LAL, USP <85>)
• Microbial limits (USP <61>/<62>)
• Stability data on request
• 503A / 503B documentation support

Regulatory note

Investigational compound in Phase 3 development (Innovent / Eli Lilly); not approved as a finished drug at the time of writing. Supplied for research use only. CAS commonly cited but should be verified per batch COA.

Selected literature

1. Ji L, Jiang H, Bi Y, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025;392(22):2215-2225.
2. Zhu D, Zhao J, Qian L, et al. Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature. 2026;652:172-180 (DREAMS-1).
3. Guo L, Zhang B, Yang W, et al. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. 2026;652:181-188 (DREAMS-2).
4. Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun. 2023;14:8289.
5. Ji L, Gao L, Jiang H, et al. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine. 2022;54:101691.
6. Azam MH, Azam MH, Azam KU, et al. Efficacy and safety of mazdutide in managing overweight and obesity among non-diabetic adults: a meta-analysis of randomised controlled trials. Diabetes Obes Metab. 2026;28(6):4464-4473.

Frequently asked questions